Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Carlyle Secured Lending NASDAQ CGBD Earnings Report Preview

Elaine Mendonca by Elaine Mendonca
February 23, 2024
in Breaking News
0
Finance_ Chart Down
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

Carlyle Secured Lending (NASDAQ: CGBD) is set to unveil its latest quarterly earnings report on February 26, 2024. Analysts are predicting an EPS of $0.52 for the company. Investors are not only hoping for a strong earnings performance but also optimistic guidance for future growth, which could have a significant impact on stock prices.

In the last quarter, Carlyle Secured Lending surpassed EPS expectations by $0.01, causing a 0.28% decline in share price the next day. As of February 22, shares were trading at $15.43, with a 52-week performance showing a slight decrease of 0.45%.

With the negative returns in mind, long-term shareholders may be feeling anxious leading up to this earnings announcement. For more information and updates on Carlyle Secured Lending’s earnings reports, individuals can visit their official website.

CGBD Stock Shows Positive Price Momentum on February 23, 2024

On February 23, 2024, CGBD stock showed positive price momentum as it traded in the middle of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been performing steadily over the long term.

The price of CGBD shares increased by $0.04 since the market last closed, representing a 0.29% rise. The stock opened at $15.50, which was $0.07 higher than its previous close. This opening price suggests that there was initial buying interest in the stock as investors anticipated further gains.

CGBD Stock Analysis: Mixed Performances in Revenue, Net Income, and EPS

On February 23, 2024, CGBD stock showed mixed performances based on the financial data provided by CNN Money. The total revenue for the company was reported at $208.22 million for the past year, showing a 9.43% increase compared to the previous year. In the third quarter, the total revenue was $60.36 million, indicating a 15.91% increase compared to the previous quarter.

However, the net income for CGBD was reported at $85.64 million for the past year, which represented a significant decrease of 46.59% compared to the previous year. In the third quarter, the net income was $29.99 million, showing a substantial increase of 536.26% compared to the previous quarter.

Earnings per share (EPS) for CGBD were reported at $1.43 for the past year, which represented a decrease of 50.58% compared to the previous year. In the third quarter, the EPS was $0.54, showing a significant increase of 608.33% compared to the previous quarter.

Overall, while CGBD showed positive growth in total revenue for both the past year and the third quarter, the net income and EPS performances were mixed. The decrease in net income and EPS for the past year is a concerning factor for investors, but the significant increase in net income and EPS for the third quarter could indicate a positive trend for the company moving forward.

Tags: CGBD
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Green energy

Anticipating Solaris Oilfield Infrastructures Quarterly Earnings Growth Potential and Caution for Investors

Investings on laptop and finances

Anticipating Freshpets Quarterly Earnings Report Analyst Projections and Investor Expectations

Healthcare cloud based

Select Healthcare Corporation Reports Impressive Q4 Results and Approves 108 Billion Buyback Program

Recommended

UBS Stock

UBS Share Buyback Fails to Impress Amid Regulatory Fears

3 months ago
IBM Stock

IBM’s UFC Partnership Showcases AI Capabilities in Live Sports

3 months ago
ImmunityBio Stock

ImmunityBio Shares Gain Momentum on Strong Revenue and Regulatory Progress

6 days ago
BioNTech Stock

BioNTech’s Billion-Euro Forecast Shift Stuns Market

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Trending

Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

by Jackson Burston
February 8, 2026
0

Investors in Rock Tech Lithium are in a holding pattern, with all eyes fixed on a pending...

Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rock Tech Lithium: Investors Await the Final Go-Ahead
  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com